Reply to M.J. Molina-Garrido et al by A. Luciani & P. Foa
Reply to M.J. Molina-Garrido et al
We would like to thank Molina-Garrido and Guille´n-Ponce1 for
their comments on our article, and appreciate this opportunity to
clarify some of the points they discussed.
The vulnerable elders survey–13 (VES-13) is a geriatric instru-
ment that has been validated as a means of indentifying elderly people
with functional decline.2 Patients are considered vulnerable if their
score is 3 or higher, and an age older than 85 years is considered a
criterion of vulnerability by itself. These criteria were established in a
cohort of nononcologic elderly patients.
The aim of our clinical trial was to compare the accuracy of
VES-13 with the Comprehensive Geriatric Assessment (CGA) in de-
tecting disabilities in elderly patients with cancer. We made an in-
trapatient analysis, and both scales were administered to every patient,
thus reducing the possible biases arising from the type of population.
Our patient series is larger than those of previously published studies,
and unlike a previous study of patients with prostate cancer3 in which
the comparison involved the CGA as a whole (including the evalua-
tion of cognitive and depressive status, which are not assessed by the
VES-13 items), we only compared homogeneous items (ie, we only
analyzed CGA functional status scores corrected for an age older than
85 years or younger than 85 years. The conclusions of our study
underline the usefulness and accuracy of VES-13 when diagnosing
impaired functional status in everyday clinical practice.
The National Comprehensive Cancer Network and the Interna-
tional Society of Geriatric Oncology guidelines3a recommend assess-
ing elderly patients with cancer by using any form of geriatric
evaluation regardless of the length of the instrument or how long it
takes to complete. There is no answer to the question as to which
instrument is the best. We believe that research should concentrate on
identifying new screening tools for assessing the impact of geriatric
impairments on oncologic outcomes (such as survival or toxicity)
rather than on finding new cutoff points for classic geriatric scales,
given that this should promote the wider use of geriatric assessments
in oncologic clinics. Multicenter and international validations are the
most appropriate methodologic means of avoiding selection biases.
The Groningen fragility index4 or Barber’s test5 do not seem to be
suitable, and the VES-13 itself is far from an ideal screening tool,
because it evaluates only one CGA dimension and is not rapid even
when self-administered. G-8 is a promising abbreviated screening
instrument that has been validated by French geriatric oncology cen-
ters, and given that it will be prospectively tested in a European Or-
ganisation for Research and Treatment of Cancer clinical trial, we
presume that it will soon be possible to draw more precise conclusions.
Many geriatric assessment instruments have been published,
none of which can be considered the best or most accurate. Clini-
cians need to be aware that any modified CGA may miss some
clinical information; modified versions should not completely re-
place the original.
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